Market revenue in 2024 | USD 241.6 million |
Market revenue in 2030 | USD 536.1 million |
Growth rate | 14.4% (CAGR from 2025 to 2030) |
Largest segment | Sequence analysis platforms |
Fastest growing segment | Sequence Analysis Platforms |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Sequence Analysis Platforms, Molecular Modelling, Docking, Clinical Trial Data Management |
Key market players worldwide | Certara Inc Ordinary Shares, Boehringer Ingelheim, Infosys Ltd ADR, Charles River Laboratories International Inc, Eli Lilly and Co, Novo Nordisk A/S ADR, Oracle Corp, Accenture PLC Class A, Agilent Technologies Inc, Illumina Inc, Eurofins Scientific SE, Jubilant Biosys, Selvita, ChemAxon, Albany Molecular Research |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug discovery informatics market will help companies and investors design strategic landscapes.
Sequence analysis platforms was the largest segment with a revenue share of 41.68% in 2024. Horizon Databook has segmented the Germany drug discovery informatics market based on sequence analysis platforms, molecular modelling, docking, clinical trial data management covering the revenue growth of each sub-segment from 2018 to 2030.
Germany has institutes and universities which are involved in development of computational tools and investigation projects related to drug discovery and development. Moreover, higher penetration of NGS services in this region which needs several data annotation and analysis tools are supportive for estimated growth of informatics market in this region.
Morphosys, Cellzome, metanomics Health, and Noxxon Pharma are the biotech companies that are engaged in development of the platforms such as Human Combinatorial Antibody Library (HuCAL). Two thirds of all R&D in Germany is financed by private companies and, most of these expenses are invested in applied projects with a clear market perspective within the industry.
A significant amount, however, is spent externally by companies on collaborative projects with academic institutions. Max Planck Society for the Advancement of Science (MPG), Helmholtz Association, Fraunhofer Society, Leibniz Association, and Max Planck Institutes are the academic organizations working on the drug discovery programs.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany drug discovery informatics market , including forecasts for subscribers. This country databook contains high-level insights into Germany drug discovery informatics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account